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Purpose   
To review the scientific literature supporting the participation of caveolin-1 in the pathogenesis 
of tissue fibrosis and that modulation of the caveolin-1 pathway may represent a novel treatment 
for systemic sclerosis (SSc) and other fibrotic diseases.  
 
Recent Findings   
Caveolin-1 plays an important role in the regulation of transforming growth factor β (TGF-β) 
signaling owing to its participation in TGF-β receptor (TβR) internalization.  TβR internalized 
through caveolin-1 lipid rafts undergoes rapid degradation, effectively decreasing TGF-β 
signaling.  Studies have shown that caveolin-1 knockdown in vitro markedly increased collagen 
gene expression in normal human lung fibroblasts.  Caveolin-1 was reduced in affected SSc 
lungs and skin and in idiopathic pulmonary fibrosis (IPF) lung tissues and fibroblasts.  Increasing 
caveolin-1 expression markedly improved bleomycin-induced pulmonary fibrosis.   Restoration 
of caveolin bioavailability employing penetratin, a cell-permeable peptide carrier for a bioactive 
caveolin-1 fragment abrogated TGF-β activation of cultured human dermal fibroblasts.  Systemic 
administration of penetratin-caveolin-1 peptide to mice with bleomycin-induced lung fibrosis 
reduced fibrosis. 
 
Summary   
Caveolin-1 plays an important role in the regulation of TGF-β signaling and participates in the 
pathogenesis of SSc and IPF.  Restoration of caveolin function employing active caveolin-1 
fragments coupled to cell-permeable carrier peptides may represent a novel approach for their 
treatment. 
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Introduction 
Fibrotic disorders, which include systemic sclerosis (SSc), idiopathic pulmonary fibrosis (IPF), 
cirrhosis of the liver, and the newly recognized Nephrogenic Systemic Fibrosis (NSF), are 
characterized by abnormal and excessive deposition of collagen and other extracellular matrix 
(ECM) components in various tissues [1-3].  Although their etiology is quite diverse, the 
presence of ECM-producing fibroblasts displaying an activated phenotype in the affected tissues 
is typical of fibrotic diseases.  Fibroblast activation is characterized by a marked increase in the 
transcriptional activity of the genes encoding type I and type III collagens and fibronectin, 
initiation of the expression of α-smooth muscle actin (α -SMA), and the reduction of ECM 
degradative activities [4].  Activated fibroblasts display contractile properties resulting from the 
expression of stress fibers containing α-SMA, and their profibrotic activation is part of a 
complex set of molecular and biochemical changes that are conserved for multiple passages in 
vitro.       
  
Transforming growth factor-β (TGF-β) plays a crucial role in fibroblast activation.  One of the 
most important effects of TGF-β  is its stimulation of ECM production and accumulation by 
increasing the expression of genes encoding various collagens and other matrix proteins and 
reducing the expression of genes involved in ECM degradation and turnover.  Delineation and 
identification of the specific cellular receptors and intracellular mediators participating in the 
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cellular response to TGF-β [1-3,5-10] and  recognition that TGF-β  is a major participant in the 
initiation and progression of tissue fibrosis have recently focused substantial attention on this 
growth factor as a target for the development of anti-fibrotic therapies [11-14].  Despite intensive 
investigations in vitro and in various animal models of fibrosis strategies to block TGF-β effects 
have thus far been ineffective or are still in the experimental stage.   
 
In the last decade, however, a novel pathway capable of exerting a potent modulation of TGF-β  
signaling has become recognized.  This pathway involves the protein caveolin-1 and caveolae, 
the cell membrane structures in which caveolin-1 is found.  Caveolin-1-positive plasma 
membrane lipid rafts called caveolae co-localize TGF-β  receptor with its degrading 
SMURF/Smad7 complex, a process which may result not only in TGF-β  signal abrogation and 
consequent fibroblast deactivation but potentially even in the restoration of the normal balance of 
ECM production and degradation.  Here, we review recent scientific literature that support the 
participation of caveolin-1 in the pathogenesis of tissue fibrosis and indicate that modulation of 
the TGF-β  pathway by strategic management of caveolin-1 bioavailability may represent a 
promising and novel therapeutic approach for fibrotic conditions such as SSc.  
 
Caveolae microdomains are crucial regulators of receptor-mediated cellular signaling   
Caveolin-1 is the most important member of a family of three membrane proteins (caveolin- 1, 2 
and 3) that are the major coating proteins of caveolae.  Caveolae are 50- to 100-nm flask-shaped 
plasma membrane invaginations that since their discovery have provoked a multitude of 
conjectures about their function [15]. Unlike earlier views of the plasma membrane as a “fluid 
mosaic” [16], which posited that integral membrane proteins float and diffuse freely through a 
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sea of homogeneous lipids, a current view is that membrane proteins are heterogeneously 
distributed and can be found clustered within specialized microdomains, termed lipid rafts, 
which are particularly rich in cholesterol and glycophosphatidylinositol-linked proteins.  
Caveolae represent a morphologically identifiable subset of lipid rafts which participate in the 
pathogenesis of numerous diseases [17-19], and extensive recent evidence has demonstrated the 
clustering of numerous receptors within their domains.  It has also been shown that the spatial 
organization of cell receptors in lipid rafts and caveolae can affect the subsequent transmission of 
the specific signal initiated by ligand engagement of these receptors [20-23].   
 
Caveolin-1 regulated TGF-β signaling  
Recent studies have shown that caveolin-1 plays a very important role in the regulation of TGF-β 
signaling owing to its participation in TβR internalization.  TβR are internalized both by 
caveolin-1 associated lipid rafts and by early endosome antigen 1 (EEA-1) non-lipid raft 
pathways.  It has been shown, furthermore, that non-lipid raft associated internalization increases 
TGF-β  signaling, whereas, caveolin-associated internalization increases TβR degradation thus, 
effectively decreasing or abolishing TGF-β  signaling [24,25].  Specifically, it was demonstrated 
that SARA and SMURF, upstream regulators of either TGF-β signaling or TβR degradation, 
respectively, were localized in distinct subcellular compartments [26,27]. The complex 
SARA/Smad2/3 which initiates TβR-1 signaling was found localized in a non-lipid raft, EEA-1 
positive compartment, whereas, the SMURF/Smad7 complex which is responsible for initiating 
proteasome degradation of TβR was found localized in caveolin-1 positive lipid rafts. The 
localization of the TβR in the EEA-1 positive compartment was responsible for downstream 
Smad activation through recruitment and phosphorylation of Smad-2/3 and subsequent nuclear 
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translocation of the Smad2/3-Smad4 complex, whereas, the localization of the TβR-I (or II) and 
receptor complex in caveolae lipid rafts caused recruitment of SMURF/Smad7 and subsequent 
receptor ubiquitination and rapid turnover.  
  
This novel mechanism of regulation of the TβR function and activity follows ligand engagement 
and is regulated by the fluidity of the membrane and the membrane density of the distinct 
caveolin-1 and non-caveolin compartments.  Thus, absence of one compartment or imbalance in 
the densities of the two compartments may affect the level of TGF-β pathway activity given the 
same amount of ligand binding.  Furthermore, since this process occurs at the level of 
internalization of the TβR immediately following ligand engagement, it likely represents an 
important mechanism of regulation of TGF-β signaling as illustrated in Figure 1.  One unique 
feature of this pathway is that it provides a cogent and plausible mechanism for the perpetuation 
of tissue fibrosis following an initial triggering event.  The triggering event results in a decrease 
in caveolin-1 gene expression; this decrease then shifts TGF-β internalization through the EEA-1 
pathway, leading to accentuation and perpetuation of the TGF-β-induced fibrotic effects and 
simultaneously causing further downregulation of caveolin-1 gene expression.  Thus, the current 
evidence indicates that caveolin-1 is a crucial regulator of TGF-β intracellular signaling and TβR 
endosomal degradation and, therefore, may play a key role in the pathogenesis of disorders 
characterized by exaggerated tissue fibrosis. 
 
Early evidence of the role of caveolin-1 in pathologic tissue fibrosis   
The earliest evidence linking caveolin-1 to a fibrotic phenotype was provided by the study of 
Kasper et al. [28] more than a decade ago.  These authors demonstrated that caveolin expression 
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was markedly downregulated in alveolar epithelium of rats and mini-pigs following radiation-
induced lung injury.  The profound downregulation of caveolin preceded the onset of radiation-
induced lung fibrosis.  Furthermore, the amount of immunoreactive caveolin correlated with the 
severity of lung fibrosis, with normal amounts present in non-affected tissue in contrast with a 
marked decrease in areas of fibrosis.  The role of caveolin-1 in the development of tissue fibrosis 
was confirmed in two independent studies which simultaneously reported the generation of mice 
lacking caveolin-1 by gene targeting [29,30].   Drab et al. [29] showed that these mice displayed 
profound histopathological and electron microscopical alterations in the lung alveolar septae, 
with replacement of the normal alveolar bilayer lining by a disorganized, multilayered structure 
containing abundant connective tissue.  Razani et al. [30] described thickened alveolar septae, 
marked hypercellularity, increased reticulin deposition and thickening of the basement 
membrane.   
 
Caveolin-1 downregulation in SSc and pulmonary fibrosis   
Subsequent studies extended the early observations described above to human diseases such as 
IPF and SSc.  Tourkina et al. [31] demonstrated that caveolin-1 knockdown in vitro resulted in a 
5-fold increase in normal human lung fibroblast collagen gene expression whereas increased 
caveolin-1 expression induced by PKC-α  caused a reduction in collagen production. The same 
study showed that fibroblasts from affected skin or lung from SSc patients contained less 
caveolin-1.  More recently, additional evidence for caveolin-1 participation in pulmonary fibrosis 
was presented.  Wang et al. [32] observed marked reduction of caveolin-1 expression in lung 
tissues and fibroblasts from IPF patients compared with controls.  Furthermore, induction of 
caveolin-1 expression with an adenovirus-caveolin-1 expression vector ameliorated bleomycin-
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induced pulmonary fibrosis.  These authors also showed that TGF-β 1 decreased caveolin-1 
expression in human lung fibroblasts and that caveolin-1 expression suppressed TGF-β 1-induced 
stimulation of ECM production in these cells.  Odajima et al. [33••] examined the expression of 
caveolin-1 during the development of bronchiolization, a key process in fibrosing lung, in mice 
with bleomycin-induced pulmonary fibrosis and in lungs from patients with various forms of 
interstitial pneumonias.  The results showed a marked decrease of caveolin-1 mRNA levels in 
the lungs from the bleomycin-treated mice as well as in bronchiolar epithelial cells isolated by 
laser capture microdissection.  Also, significant reduction in caveolin-1 protein and mRNA 
levels were found in affected tissues from patients with pulmonary fibrosis.  Thus, the results of 
these studies collectively supported a pivotal role for caveolin-1 in the pathogenesis of 
pulmonary fibrosis.   
 
Recently our group demonstrated that caveolin downregulation is also an important feature of 
SSc [34••].  In these studies we found a substantial reduction in caveolin-1 immunofluorescence 
in affected SSc lungs and skin in contrast with normal caveolin-1 expression in 
histopathologically non-affected areas (Figure 2). Furthermore, TGF-β  treatment of normal 
dermal fibroblasts induced a potent downregulation of caveolin-1 expression. These findings 
suggested that the observed decrease in caveolin-1 expression in SSc affected tissues may have 
been caused by TGF-β  or other cytokines released by inflammatory cells present in the tissue and 
could in turn be responsible for further amplification of TGF-β  signaling, a crucial event in the 
pathogenesis of tissue fibrosis in SSc.  Specifically, as depicted in Figure 1, decreased caveolin-
1 expression in SSc would be responsible for an amplification loop of TGF-β  signaling; the 
increase in TGF-β  signaling causing, in turn, a further downregulation of caveolin expression at 
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both the mRNA and protein levels, triggering a repetitive cycle of signal amplification that 
ultimately leads to tissue fibrosis.  
 
Caveolin-null mice and tissue fibrosis 
Early studies on caveolin-1 null mice [29,30] described thickening of lung alveolar septa caused 
by proliferation of endothelial cells and accumulation of reticulin and other matrix proteins, 
however, they did not describe whether the caveolin-1-null animals had evidence of fibrosis in 
other tissues.  We performed an extensive histopathologic analysis and measured the 
hydroxyproline content of skin and lungs of caveolin-1 knockout mice [34••].  The results 
indicated that as early as 12 weeks of age, caveolin-1-null mice displayed a marked increase in 
collagen deposition in skin and lungs compared with their normal littermates (Figure 3).  These 
histopathological changes were accompanied by a threefold increase in lung and skin collagen 
content.  In vitro studies performed with caveolin-1 null fibroblasts indicated that the observed 
tissue fibrosis was associated with a profibrotic phenotype of tissue fibroblasts strikingly similar 
to that of SSc fibroblasts. These data indicate that the lung involvement in caveolin-1-null mice 
is secondary to a combination of pulmonary artery hypertension resulting from the known hyper-
proliferative phenotype of caveolin-1-null vascular smooth muscle cells and their increased 
sensitivity to endothelin-1 [35,36] combined with parenchymal lung fibrosis caused by the 
profibrotic gene expression pattern of caveolin-1 null fibroblasts.  
 
The role of caveolin-1 in lung fibrosis has been indirectly confirmed by a study in which specific 
endothelial overexpression of caveolin-1 was induced in caveolin-1 knockout mice.  Selective re-
expression of caveolin-1 in endothelial cells partially reverted the phenotype of pulmonary artery 
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hypertension, whereas, in contrast, the extent of lung parenchymal fibrosis was not affected by 
the endothelial cell-specific rescue of caveolin-1 expression [37••]. 
 
Restoration of caveolin-1 levels as a therapeutic approach for fibrotic diseases 
The data summarized here provide robust evidence supporting the involvement of caveolin-1 
downregulation in the pathogenesis of tissue fibrosis. The next logical step, as suggested in a 
recently published editorial [38••] is to develop therapeutic tools that may increase caveolin-1 
bioavailability in the target cells.  One of the most promising and novel approaches to 
accomplish this goal is the utilization of cell permeable carriers capable of shuttling small 
peptides and proteins inside cells [39].  One such carrier is penetratin, a 16-amino acid-long 
fragment of the third helix of the homeodomain of the Antennapedia homeoprotein [40]. 
Penetratin is internalized by cells in a specific, non-receptor-mediated manner, and is able to 
translocate through the cell membrane [40].  On the other hand, Razani et al. [41] demonstrated 
previously that the interaction between caveolin-1 and the TβR was mediated by a small region 
within the caveolin-1 protein identified as the caveolin scaffolding domain (CSD) which 
specifically recognizes and binds to a short amino acid sequence termed the caveolin binding 
motif present in TβR and other serine-threonine kinases.  Numerous studies have provided ample 
experimental evidence that the caveolin-1 kinase inhibitor function is mediated by the CSD 
[42,43] and in some studies caveolin-1 function has been restored following successful delivery 
of the CSD to cells employing a penetratin-CSD fusion cell permeable peptide.  
 
In our studies [34••] we employed the CSD-penetratin fusion peptide to explore the effects of 
caveolin-1 function restoration on the profibrotic phenotype of SSc fibroblasts and on the effects 
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of exogenous TGF-β stimulation.  We found that the CSD-penetratin fusion peptide was not 
cytotoxic, inhibited the increased collagen production and α-SMA expression in SSc dermal 
fibroblasts, and suppressed TGF-β stimulation of collagen and α-SMA expression.  Furthermore, 
the peptide inhibited TGF-β induced Smad2/3 nuclear translocation. Similar studies were 
recently published by Tourkina et al. [44••], who, employing the same peptide on SSc lung 
fibroblasts in vitro demonstrated an inhibitory effect of important non-Smad intracellular 
signaling TGF-β pathways including MEK, ERK, JNK, and Akt.  Of further interest was their 
demonstration that systemic administration of CSD-penetratin peptide to mice with bleomycin-
induced lung fibrosis blocked epithelial cell apoptosis and inflammatory cell infiltration and 
reduced fibrotic changes, thus supporting the potential efficacy of this treatment for SSc and 
pulmonary fibrosis.  
 
Conclusion 
Numerous studies published during the last decade have provided strong evidence that caveolin-
1, the main protein component of caveolae, participates in the pathogenesis of fibrotic diseases 
through regulation of TβR degradation and activation.  A profound reduction in caveolin-1 
expression has been demonstrated in affected tissues from IPF and SSc patients, and the 
important role of the protein in TGF-β signaling and stimulation of ECM production has been 
conclusively demonstrated.  Restoration of caveolin-1 function employing novel cell-permeable 
peptides coupled to active caveolin-1 fragments abrogated the profibrotic effects of TGF-β and, 
therefore, may represent a novel treatment for SSc and other fibrotic disorders.   
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Legends to Figures  
 
Figure 1.  Schematic diagram for the involvement of caveolae in TGF-β signal transduction and 
for the mechanisms whereby caveolin-1 downregulation in SSc would result in tissue fibrosis 
and further caveolin-1 downregulation (adapted from ref. 25). 
 
Figure 2. Reduction of caveolin-1 expression in SSc lung and skin.  A. Confocal image of 
normal lung immunostained for caveolin-1. Note the homogeneous green membrane staining for 
caveolin-1 on the surface of alveolar wall cells. B and C. Confocal image of SSc lung stained for 
caveolin-1. Note that in contrast with A, there is low expression of caveolin-1 in most cells of the 
vessel wall and interstitium.  D. Normal skin. Note the expression of caveolin-1 surrounding 
almost every cell in the dermis.  E. SSc skin. Note the low expression of caveolin-1 in most cells.  
F. Cell lysates from two SSc dermal fibroblast cell lines and two normal dermal fibroblast cell 
lines analyzed by Western blot for caveolin-1. Reproduced from ref. 34 with permission form 
Arthritis Rheum. 
 
Figure 3.  Increased collagen in lungs and skin of caveolin-1 knockout mice. A. Masson’s 
Trichrome staining for collagen in interstitium of wild type (WT) and caveolin-1 null lung 
(CAV). B.  Masson’s Trichrome staining for collagen in the skin of wild type (WT) and 
caveolin-1 null skin (CAV).  Reproduced from ref. 34 with permission from Arthritis Rheum. 
  
